The conference highlighted strong execution on pivotal cema-cel trials, rapid MRD testing adoption, and a sizable market opportunity. Interim data showed high MRD clearance and excellent safety, while ALLO-329's dual-targeting and Dagger technology drive innovation in autoimmune indications.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.